https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-next-gen-obesity-drug-cagrisema-achieves-lower-weight-loss-than-2024-12-20/
0
0
12/20/24 at 6:06am
Organization
Reuters
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Create an account
or login to join the discussion